Copyright Reports & Markets. All rights reserved.

Global Alzheimer’s Agitation Treatment Market Insights, Forecast to 2028

Buy now

1 Study Coverage

  • 1.1 Alzheimer’s Agitation Treatment Product Introduction
  • 1.2 Market by Type
  • 1.2.1 Global Alzheimer’s Agitation Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Donepezil
  • 1.2.3 Galantamine
  • 1.2.4 Rivastigmine
  • 1.3 Market by Application
  • 1.3.1 Global Alzheimer’s Agitation Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 General Hospitals
  • 1.3.3 Specialty Clinics
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Executive Summary

    • 2.1 Global Alzheimer’s Agitation Treatment Sales Estimates and Forecasts 2017-2028
    • 2.2 Global Alzheimer’s Agitation Treatment Revenue Estimates and Forecasts 2017-2028
    • 2.3 Global Alzheimer’s Agitation Treatment Revenue by Region: 2017 VS 2021 VS 2028
    • 2.4 Global Alzheimer’s Agitation Treatment Sales by Region
    • 2.4.1 Global Alzheimer’s Agitation Treatment Sales by Region (2017-2022)
  • 2.4.2 Global Sales Alzheimer’s Agitation Treatment by Region (2023-2028)
  • 2.5 Global Alzheimer’s Agitation Treatment Revenue by Region
  • 2.5.1 Global Alzheimer’s Agitation Treatment Revenue by Region (2017-2022)
  • 2.5.2 Global Alzheimer’s Agitation Treatment Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa
  • 3 Competition by Manufacturers

    • 3.1 Global Alzheimer’s Agitation Treatment Sales by Manufacturers
    • 3.1.1 Global Top Alzheimer’s Agitation Treatment Manufacturers by Sales (2017-2022)
  • 3.1.2 Global Alzheimer’s Agitation Treatment Sales Market Share by Manufacturers (2017-2022)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Alzheimer’s Agitation Treatment in 2021
  • 3.2 Global Alzheimer’s Agitation Treatment Revenue by Manufacturers
  • 3.2.1 Global Alzheimer’s Agitation Treatment Revenue by Manufacturers (2017-2022)
  • 3.2.2 Global Alzheimer’s Agitation Treatment Revenue Market Share by Manufacturers (2017-2022)
  • 3.2.3 Global Top 10 and Top 5 Companies by Alzheimer’s Agitation Treatment Revenue in 2021
  • 3.3 Global Alzheimer’s Agitation Treatment Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Alzheimer’s Agitation Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Alzheimer’s Agitation Treatment Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans
  • 4 Market Size by Type

    • 4.1 Global Alzheimer’s Agitation Treatment Sales by Type
    • 4.1.1 Global Alzheimer’s Agitation Treatment Historical Sales by Type (2017-2022)
  • 4.1.2 Global Alzheimer’s Agitation Treatment Forecasted Sales by Type (2023-2028)
  • 4.1.3 Global Alzheimer’s Agitation Treatment Sales Market Share by Type (2017-2028)
  • 4.2 Global Alzheimer’s Agitation Treatment Revenue by Type
  • 4.2.1 Global Alzheimer’s Agitation Treatment Historical Revenue by Type (2017-2022)
  • 4.2.2 Global Alzheimer’s Agitation Treatment Forecasted Revenue by Type (2023-2028)
  • 4.2.3 Global Alzheimer’s Agitation Treatment Revenue Market Share by Type (2017-2028)
  • 4.3 Global Alzheimer’s Agitation Treatment Price by Type
  • 4.3.1 Global Alzheimer’s Agitation Treatment Price by Type (2017-2022)
  • 4.3.2 Global Alzheimer’s Agitation Treatment Price Forecast by Type (2023-2028)
  • 5 Market Size by Application

    • 5.1 Global Alzheimer’s Agitation Treatment Sales by Application
    • 5.1.1 Global Alzheimer’s Agitation Treatment Historical Sales by Application (2017-2022)
  • 5.1.2 Global Alzheimer’s Agitation Treatment Forecasted Sales by Application (2023-2028)
  • 5.1.3 Global Alzheimer’s Agitation Treatment Sales Market Share by Application (2017-2028)
  • 5.2 Global Alzheimer’s Agitation Treatment Revenue by Application
  • 5.2.1 Global Alzheimer’s Agitation Treatment Historical Revenue by Application (2017-2022)
  • 5.2.2 Global Alzheimer’s Agitation Treatment Forecasted Revenue by Application (2023-2028)
  • 5.2.3 Global Alzheimer’s Agitation Treatment Revenue Market Share by Application (2017-2028)
  • 5.3 Global Alzheimer’s Agitation Treatment Price by Application
  • 5.3.1 Global Alzheimer’s Agitation Treatment Price by Application (2017-2022)
  • 5.3.2 Global Alzheimer’s Agitation Treatment Price Forecast by Application (2023-2028)
  • 6 North America

    • 6.1 North America Alzheimer’s Agitation Treatment Market Size by Type
    • 6.1.1 North America Alzheimer’s Agitation Treatment Sales by Type (2017-2028)
  • 6.1.2 North America Alzheimer’s Agitation Treatment Revenue by Type (2017-2028)
  • 6.2 North America Alzheimer’s Agitation Treatment Market Size by Application
  • 6.2.1 North America Alzheimer’s Agitation Treatment Sales by Application (2017-2028)
  • 6.2.2 North America Alzheimer’s Agitation Treatment Revenue by Application (2017-2028)
  • 6.3 North America Alzheimer’s Agitation Treatment Market Size by Country
  • 6.3.1 North America Alzheimer’s Agitation Treatment Sales by Country (2017-2028)
  • 6.3.2 North America Alzheimer’s Agitation Treatment Revenue by Country (2017-2028)
  • 6.3.3 United States
  • 6.3.4 Canada
  • 7 Europe

    • 7.1 Europe Alzheimer’s Agitation Treatment Market Size by Type
    • 7.1.1 Europe Alzheimer’s Agitation Treatment Sales by Type (2017-2028)
  • 7.1.2 Europe Alzheimer’s Agitation Treatment Revenue by Type (2017-2028)
  • 7.2 Europe Alzheimer’s Agitation Treatment Market Size by Application
  • 7.2.1 Europe Alzheimer’s Agitation Treatment Sales by Application (2017-2028)
  • 7.2.2 Europe Alzheimer’s Agitation Treatment Revenue by Application (2017-2028)
  • 7.3 Europe Alzheimer’s Agitation Treatment Market Size by Country
  • 7.3.1 Europe Alzheimer’s Agitation Treatment Sales by Country (2017-2028)
  • 7.3.2 Europe Alzheimer’s Agitation Treatment Revenue by Country (2017-2028)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia
  • 8 Asia Pacific

    • 8.1 Asia Pacific Alzheimer’s Agitation Treatment Market Size by Type
    • 8.1.1 Asia Pacific Alzheimer’s Agitation Treatment Sales by Type (2017-2028)
  • 8.1.2 Asia Pacific Alzheimer’s Agitation Treatment Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Alzheimer’s Agitation Treatment Market Size by Application
  • 8.2.1 Asia Pacific Alzheimer’s Agitation Treatment Sales by Application (2017-2028)
  • 8.2.2 Asia Pacific Alzheimer’s Agitation Treatment Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Alzheimer’s Agitation Treatment Market Size by Region
  • 8.3.1 Asia Pacific Alzheimer’s Agitation Treatment Sales by Region (2017-2028)
  • 8.3.2 Asia Pacific Alzheimer’s Agitation Treatment Revenue by Region (2017-2028)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 China Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 9 Latin America

    • 9.1 Latin America Alzheimer’s Agitation Treatment Market Size by Type
    • 9.1.1 Latin America Alzheimer’s Agitation Treatment Sales by Type (2017-2028)
  • 9.1.2 Latin America Alzheimer’s Agitation Treatment Revenue by Type (2017-2028)
  • 9.2 Latin America Alzheimer’s Agitation Treatment Market Size by Application
  • 9.2.1 Latin America Alzheimer’s Agitation Treatment Sales by Application (2017-2028)
  • 9.2.2 Latin America Alzheimer’s Agitation Treatment Revenue by Application (2017-2028)
  • 9.3 Latin America Alzheimer’s Agitation Treatment Market Size by Country
  • 9.3.1 Latin America Alzheimer’s Agitation Treatment Sales by Country (2017-2028)
  • 9.3.2 Latin America Alzheimer’s Agitation Treatment Revenue by Country (2017-2028)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina
  • 9.3.6 Colombia
  • 10 Middle East and Africa

    • 10.1 Middle East and Africa Alzheimer’s Agitation Treatment Market Size by Type
    • 10.1.1 Middle East and Africa Alzheimer’s Agitation Treatment Sales by Type (2017-2028)
  • 10.1.2 Middle East and Africa Alzheimer’s Agitation Treatment Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Alzheimer’s Agitation Treatment Market Size by Application
  • 10.2.1 Middle East and Africa Alzheimer’s Agitation Treatment Sales by Application (2017-2028)
  • 10.2.2 Middle East and Africa Alzheimer’s Agitation Treatment Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Alzheimer’s Agitation Treatment Market Size by Country
  • 10.3.1 Middle East and Africa Alzheimer’s Agitation Treatment Sales by Country (2017-2028)
  • 10.3.2 Middle East and Africa Alzheimer’s Agitation Treatment Revenue by Country (2017-2028)
  • 10.3.3 Turkey
  • 10.3.4 Saudi Arabia
  • 11 Company Profiles

    • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Corporation Information
  • 11.1.2 AstraZeneca Overview
  • 11.1.3 AstraZeneca Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.1.4 AstraZeneca Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 AstraZeneca Recent Developments
  • 11.2 Biogen
  • 11.2.1 Biogen Corporation Information
  • 11.2.2 Biogen Overview
  • 11.2.3 Biogen Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.2.4 Biogen Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Biogen Recent Developments
  • 11.3 Bristol Myers Squibb
  • 11.3.1 Bristol Myers Squibb Corporation Information
  • 11.3.2 Bristol Myers Squibb Overview
  • 11.3.3 Bristol Myers Squibb Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.3.4 Bristol Myers Squibb Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Bristol Myers Squibb Recent Developments
  • 11.4 Eisai
  • 11.4.1 Eisai Corporation Information
  • 11.4.2 Eisai Overview
  • 11.4.3 Eisai Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.4.4 Eisai Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Eisai Recent Developments
  • 11.5 Eli Lilly and Company
  • 11.5.1 Eli Lilly and Company Corporation Information
  • 11.5.2 Eli Lilly and Company Overview
  • 11.5.3 Eli Lilly and Company Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.5.4 Eli Lilly and Company Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Eli Lilly and Company Recent Developments
  • 11.6 Glaxo Smith Kline
  • 11.6.1 Glaxo Smith Kline Corporation Information
  • 11.6.2 Glaxo Smith Kline Overview
  • 11.6.3 Glaxo Smith Kline Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.6.4 Glaxo Smith Kline Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Glaxo Smith Kline Recent Developments
  • 11.7 H. Lundbeck
  • 11.7.1 H. Lundbeck Corporation Information
  • 11.7.2 H. Lundbeck Overview
  • 11.7.3 H. Lundbeck Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.7.4 H. Lundbeck Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 H. Lundbeck Recent Developments
  • 11.8 Johnson and Johnson
  • 11.8.1 Johnson and Johnson Corporation Information
  • 11.8.2 Johnson and Johnson Overview
  • 11.8.3 Johnson and Johnson Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.8.4 Johnson and Johnson Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 Johnson and Johnson Recent Developments
  • 11.9 Novartis
  • 11.9.1 Novartis Corporation Information
  • 11.9.2 Novartis Overview
  • 11.9.3 Novartis Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.9.4 Novartis Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 Novartis Recent Developments
  • 11.10 Ono Pharmaceutical
  • 11.10.1 Ono Pharmaceutical Corporation Information
  • 11.10.2 Ono Pharmaceutical Overview
  • 11.10.3 Ono Pharmaceutical Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.10.4 Ono Pharmaceutical Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Ono Pharmaceutical Recent Developments
  • 11.11 Otsuka Holdings
  • 11.11.1 Otsuka Holdings Corporation Information
  • 11.11.2 Otsuka Holdings Overview
  • 11.11.3 Otsuka Holdings Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.11.4 Otsuka Holdings Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 Otsuka Holdings Recent Developments
  • 11.12 Pfizer
  • 11.12.1 Pfizer Corporation Information
  • 11.12.2 Pfizer Overview
  • 11.12.3 Pfizer Alzheimer’s Agitation Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.12.4 Pfizer Alzheimer’s Agitation Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.12.5 Pfizer Recent Developments
  • 12 Industry Chain and Sales Channels Analysis

    • 12.1 Alzheimer’s Agitation Treatment Industry Chain Analysis
    • 12.2 Alzheimer’s Agitation Treatment Key Raw Materials
    • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Alzheimer’s Agitation Treatment Production Mode & Process
  • 12.4 Alzheimer’s Agitation Treatment Sales and Marketing
  • 12.4.1 Alzheimer’s Agitation Treatment Sales Channels
  • 12.4.2 Alzheimer’s Agitation Treatment Distributors
  • 12.5 Alzheimer’s Agitation Treatment Customers
  • 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

    • 13.1 Alzheimer’s Agitation Treatment Industry Trends
    • 13.2 Alzheimer’s Agitation Treatment Market Drivers
    • 13.3 Alzheimer’s Agitation Treatment Market Challenges
    • 13.4 Alzheimer’s Agitation Treatment Market Restraints

    14 Key Findings in The Global Alzheimer’s Agitation Treatment Study

      15 Appendix

      • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
    • 15.2 Author Details
    • Market Analysis and Insights: Global Alzheimer’s Agitation Treatment Market
      Due to the COVID-19 pandemic, the global Alzheimer’s Agitation Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Donepezil accounting for % of the Alzheimer’s Agitation Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While General Hospitals segment is altered to an % CAGR throughout this forecast period.

      China Alzheimer’s Agitation Treatment market size is valued at US$ million in 2021, while the US and Europe Alzheimer’s Agitation Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Alzheimer’s Agitation Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

      The global key manufacturers of Alzheimer’s Agitation Treatment include AstraZeneca, Biogen, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Glaxo Smith Kline, H. Lundbeck, Johnson and Johnson and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

      Market Segments

      The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

      Segment by Type

      Donepezil

      Galantamine

      Rivastigmine

      Segment by Application

      General Hospitals

      Specialty Clinics

      Consequence of Covid-19 Pandemic

      The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Alzheimer’s Agitation Treatment market back to the pre-covid levels.

      Trends & Prospects

      In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

      By Region

      North America

      United States

      Canada

      Europe

      Germany

      France

      U.K.

      Italy

      Russia

      Asia-Pacific

      China

      Japan

      South Korea

      India

      Australia

      China Taiwan

      Indonesia

      Thailand

      Malaysia

      Latin America

      Mexico

      Brazil

      Argentina

      Colombia

      Middle East & Africa

      Turkey

      Saudi Arabia

      UAE

      Competitive Outlook

      In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

      AstraZeneca

      Biogen

      Bristol Myers Squibb

      Eisai

      Eli Lilly and Company

      Glaxo Smith Kline

      H. Lundbeck

      Johnson and Johnson

      Novartis

      Ono Pharmaceutical

      Otsuka Holdings

      Pfizer

      Frequently Asked Questions

      Which is the most lucrative product segment in the Alzheimer’s Agitation Treatment market?

      Which are the prominent strategies of the Alzheimer’s Agitation Treatment market players?

      Which factors are increasing the competition in the Alzheimer’s Agitation Treatment market?

      Which are the recommendations provided by the Alzheimer’s Agitation Treatment industry experts?

      Which region will witness rewarding growth during the forecast period?

      What factors will curb the Alzheimer’s Agitation Treatment market growth?

      Which product segment will register the fastest growth rate in the Alzheimer’s Agitation Treatment market?

      Which emerging trends will impact the Alzheimer’s Agitation Treatment market growth?

      Which are the high-impact rendering factors in the Alzheimer’s Agitation Treatment market?

      Which companies will maintain their lead on the Alzheimer’s Agitation Treatment market?

      Buy now